Trial Profile
A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir(R) Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin detemir (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 29 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 08 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov